CREBBP and cancer: By contrast, the β-catenin inhibitor PRI-724 directly targets the protein–protein interaction of β-catenin with the CREB-binding protein (CBP) to inhibit Wnt signaling in various cancer models [11,12,13,39,40,41,42,43].